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Summary
QUESTIONS UNDER STUDY: To describe acute toxicity
of recreational drugs including novel psychoactive sub-
stances.
METHODS: We included all cases presenting at the emer-
gency department (ED) of the University Hospital of Basel,
Switzerland, between October 2013 and September 2014
with acute toxicity due to self-reported recreational drug
use or with symptoms/signs consistent with acute toxicity.
Isolated ethanol intoxications were excluded. Intoxications
were confirmed with immunoassays and liquid chroma-
tography coupled with mass spectrometry (LC-MS/MS),
which also detected novel psychoactive substances.
RESULTS: Among the 47,767 attendances at the ED, 216
were directly related to acute toxicity of recreational drugs.
The mean patient age was 31 years and 69% were male.
Analytical drug confirmation was available in 180 cases.
Most presentations were related to cocaine (36%), cannabis
(31%), opioids (13%), 3,4-methylenedioxy-methamphet-
amine (MDMA, 9%), other amphetamines (7%), benzo-
diazepines (7%), and lysergic acid diethylamide (LSD,
5%). The substances most commonly detected analytically
were cannabis (37%), cocaine (33%), opioids (29%), ben-
zodiazepines (21%), and amphetamines including MDMA
(13%). Notably, there were only two cases of novel psycho-
active substances (2,5-dimethoxy-4-bromophenethylamine
[2C-B] and pentylone). The most frequent symptoms were
tachycardia (31%), anxiety (27%), nausea or vomiting
(23%), and agitation (22%). Severe complications included
myocardial infarction (2), psychosis (10), seizures (10),
and 1 fatality. Most patients were discharged home (68%),
8% were admitted to intensive care and 9% were referred
to psychiatric care.
CONCLUSION: Medical problems related to illicit drugs
mostly concerned cocaine and cannabis and mainly in-
volved sympathomimetic toxicity and/or psychiatric disor-
ders. ED presentations associated with novel psychoactive
substances appeared to be relatively rare.
Key words: recreational drugs; acute toxicity;
psychoactive substances
Introduction
The misuse of illegal psychoactive substances for recre-
ational purposes is common. It is estimated that nearly
a quarter of the adult population in the European Union
have used illicit substances at some point in their lives
[1]. Novel psychoactive substances have emerged in recent
years in response to market trends and legislative control
[2]. Currently, approximately one novel psychoactive sub-
stance is identified in Europe per week [3]. Novel psycho-
active substances are typically not detected with the im-
munoassays commonly used as screening tests. There are
limited data on drug-related health emergencies, in partic-
ular regarding novel psychoactive substances [4, 5]. The
study centre is part of the European Drug Emergencies
Network (Euro-DEN), which collects data on acute recre-
ational drug and novel psychoactive substance toxicity [4].
The present study aimed to describe demographics, clinic-
al findings, substances used and short-term outcome of pa-
tients with acute medical problems due to recreational il-
licit substance use presenting to a large urban emergency
department in Switzerland over a period of 1 year. Ad-
ditionally, the study screened for novel psychoactive sub-
stances in serum using a liquid chromatography coupled
with mass spectrometry (LC-MS/MS) screening method.
Material and methods
This study was approved by the ethics committee. We in-
cluded all patients admitted to the Emergency Department
(ED) of the University Hospital of Basel with acute recre-
ational drug-related medical problems between 1 October
2013 and 30 September 2014. The ED is both a primary
care facility (walk-in patients) and a tertiary referral centre
for hospitals in the greater Basel area. Additionally, all pa-
tients brought by paramedics are first admitted to the ED.
All ED presentations are entered into the comprehensive
electronic patient chart data-base from which cases were
retrieved at monthly intervals using a comprehensive full-
text search algorithm. In brief, the sensitive automatic
search identified all cases with notions of abuse, intox-
ication or related terms and a large number of substance
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names including abbreviations and misspellings. The
charts of all cases were reviewed, including notes by para-
medics. Only patients with acute toxicity were included.
A recreational drug was defined as “a psychoactive com-
pound that was taken for the purpose of recreational activ-
ities rather than for medical or work purposes or for self-
harm”. We identified the recreational drug(s) associated
with the presentation based on one or a combination of the
following: the patient’s self-reported use, information re-
trieved from witnesses, the opinion of the physician assess-
ing the patient and/or the analytical confirmation. Cases in
which no information was available from the patient (be-
cause of coma on presentation, unwillingness to cooperate,
language problems, etc.) but the symptoms on presentation
and the analytical test results – if available ‒ were typical
of acute recreational drug toxicity were also included. Data
were abstracted in a standardised manner [4, 6] by one of
the authors for the entire study. Data were collected within
the Euro-DEN project [4]. Exclusion criteria were: isolated
ethanol intoxication, drug withdrawal and secondary com-
plications of chronic drug use (e.g. infected injection sites).
We recorded the patient demographics (age, sex, hour and
week day of ED admission), the substances used as re-
ported by the patient or witnesses, the clinical effects, and
clinical outcome. Clinical variables included the Glasgow
Coma Scale (GCS) score, heart rate, blood pressure, respir-
atory rate, body temperature, laboratory tests and electro-
cardiography (ECG) findings. In cases where the Glasgow
Coma Score was not recorded, either ‘alert’, ‘drowsy’ or
‘coma’ was used, based on the notes of the treating clini-
cian. Hyperthermia was defined as a temperature ≥39 °C,
hypertension as a systolic blood pressure ≥180 mm Hg, hy-
potension as a systolic blood pressure ≤90 mm Hg. Sever-
ity of poisoning was assessed using the Poison Severity
Score for grading acute poisoning [7]. Mild toxicity refers
to mild, transient and spontaneously resolving symptoms,
moderate toxicity refers to pronounced or prolonged symp-
toms, and severe toxicity indicates severe or life-threaten-
ing symptoms.
The CEDIA immunoassay (Thermo Fisher Scientific, Pas-
sau, Germany) was used to screen for barbiturates, amphet-
amines (including 3,4-methylenedioxy-methamphetamine
[MDMA]), benzodiazepines, cocaine, tetrahydrocannabin-
ol (THC), methadone and 6-monoacetyl morphine
(6-MAM). The DRI immunoassay (Thermo Fisher
Scientific, Passau, Germany) was used to screen for tri-
cyclic antidepressants and opiates. Ethanol blood levels
were determined with an enzyme assay. Additionally, li-
quid chromatography coupled with mass spectrometry
(LC-MS) analysis with a method covering over 700 sub-
stances was applied for confirmation and to detect addi-
tional substances in 100 of the cases (64%) [8]. Levels
of γ-hydroxybutyrate (GHB) were determined with an en-
zymatic assay (Bühlmann, Allschwil, Switzerland).
Results
From a total of 47,767 patient admissions to the ED during
the study period, 216 cases were related to acute drug tox-
icity and therefore included in the present study. During the
same time period there were 476 admissions due to acute
recreational ethanol use with or without co-use of other re-
creational drugs. Sixty percent of the patients reported use
of only one substance. Concomitant use of alcohol was re-
ported in 48% of the cases. In 18 cases (8%) there was no
information available on the agents taken and 8 patients
(4%) denied having used any drugs. These patients were
included because they were judged by the assessing phys-
ician as being acutely intoxicated based on the symptoms
and/or analytical confirmation. The demographic data are
presented in table 1. The mean patient age was 31 years and
most patients were male. Most patients were admitted to
the ED at night and/or on weekends, and half of them were
brought to the ED by ambulance.
The most commonly self-reported recreational drugs were
cocaine and cannabis (table 2). Sixteen patients (7%) repor-
ted that they had used a substance without knowing what
it was. An analytical confirmation was available in 83% of
the total cases (immunoassay in 180 cases, additional LC-
MS/MS in 100 cases) (table 2).
Table 3 summarises the medical problems. The most com-
monly reported symptoms were tachycardia, anxiety, naus-
ea or vomiting, and agitation. Most patients (68%) were
medically discharged after spending less than 24 hours at
the ED; in 21 cases (10%) the patients took their own dis-
charge or left the ED before being seen by a doctor (table
4). Seventeen patients (8%) were admitted to the critical
care unit, and in 11 cases (5%) the patients were hospital-
ised in other wards of the hospital. Twenty patients (9%)
were admitted to a psychiatric institution and one patient
was admitted to the gynaecology and to the forensic depart-
ments because of suspected rape.
Table 1: Patient characteristics.
Number of cases
N = 216 (%)
Male 148 (69)
Female 68 (31)
Age, years
16–20 42 (19)
21–30 79 (37)
31–40 55 (25)
>40 40 (19)
Time of presentation
Night arrival (20:00 – 8:00 h) 118 (55)
Weekend arrival (Friday 17:00 h –
Monday 8:00 h)
125 (58)
Ethanol co-ingested (self-reported)
Yes 103 (48)
No 8 (4)
Not known 105 (49)
Self-reported drug use
1 substance 129 (60)
>1 substances 61 (28)
No drug use 8 (4)
No information available from the patient
(language, coma, etc.)
18 (8)
Laboratory-confirmed drug use
1 substance 63 (29)
>1 substances 96 (44)
No drugs confirmed (absence or insufficient
sensitivity of test)
21 (10)
No drug test performed 36 (17)
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In 174 cases (81%) medical treatment including oxygen
and intravenous fluid administration was provided.
Tracheal intubation was performed in 5 cases (2%). Sed-
ating drugs were administered including benzodiazepines
in 51 cases (24%), propofol in 3 cases (1%), and anti-
psychotics (chlorprothixene and haloperidol, each used in
one case). Naloxone was administered in 17 cases (8%),
flumazenil in 6 cases (3%), activated charcoal in one case,
and biperiden for dystonia in one case.
Among all 216 cases, 40 (19%) presented with severe in-
toxication and there was one fatality after intravenous drug
use. In 28 of the 40 severe intoxication cases concomitant
use of alcohol was reported and/or analytically confirmed.
Two cases of myocardial infarction (both without ST elev-
ation) were observed, of these patients one reported use of
amphetamine and LSD (amphetamine and THC use analyt-
ically confirmed) and the other was a regular drug user in
a methadone substitution programme who reported having
used cocaine (cocaine, cannabis, benzodiazepine and meth-
adone use were analytically confirmed). Both patients were
hospitalised, the first was initially admitted to the critic-
al care unit and underwent coronary angiography; stenting
was not needed.
Ten cases (5%) of seizures occurred. From these patients,
three had a medical history of epilepsy and five were regu-
lar drug users. Two of the patients were kept by the police
at the moment of the seizure (one in jail and one in a
sobering-up cell). Hyponatraemia (sodium 116 mmol/l on
presentation, reference range 135–145 mmol/l), hypervent-
ilation, insomnia, alcohol withdrawal, cannabis withdraw-
al, and i.v. use of contaminated heroin were considered as
differential diagnoses regarding the cause of the seizure in
four of the cases. In eight cases the seizure was observed
by others (seven cases of generalised seizures and one case
of extremities’ spasms without loss of consciousness). In
one case a seizure during the night was suspected because
of enuresis and creatine kinase elevation, and in one case
the diagnosis of a seizure was based on the patient’s report
only. Three of the patients with seizures reported use of
cocaine, three of cannabis, one of heroin, one of MDMA,
one of an unknown agent, and in one case there was no in-
formation available. Substances that were analytically con-
firmed among these cases were cocaine, cannabis, methad-
one, opioids, MDMA, and benzodiazepines (in one of the
cases given by the paramedics). According to the self-re-
ports, nine of the ten patients had used only one substance,
in the toxicological analysis however, more than one sub-
stances were found in six of the ten cases.
Among the 10 cases with psychosis the substances that
were self-reported were cocaine, cannabis, heroin, MDMA,
ketamine, methadone, LSD and tramadol (use of only one
substance in five cases (50%) according to self-report). The
toxicological analysis of those cases revealed also the use
of opioids (other than tramadol), mescaline (in two cases),
amphetamine (other than MDMA), benzodiazepine, and
pentylone (in the tramadol self-report case). According to
the analytical confirmation one substance was used only in
one of the ten cases (10%). In the case of LSD self-report
(patient naked and very aggressive on presentation) a high
LSD blood concentration was found. The symptoms that
Table 2: Substance use characteristics.
Number of cases N = 216 (%)
Self-reported (%) Analytically confirmed (%)
Cocaine 77 (36) 72 (33)
Cannabis 68 (31) 79 (37)
Benzodiazepines 16 (7) 45 (21)
Barbiturates 1 (<0.5)
Opioids (excluding methadone and heroin) 4 (2) 33 (15)
Heroin 15 (7) 6 (3)
Methadone 9 (4) 23 (11)
MDMA/ecstasy 19 (9)
Amphetamine/methamphetamine 15 (7)
28 (13)
LSD 11 (5) 5 (2)
GHB 2 (1) 1 (<0.5)
Magic mushrooms/psilocybin 1 (<0.5) 1 (<0.5)
Pentylone 1 (<0.5)
Mescaline 4 (2)
Poppers (alkyl nitrites) 2 (1)
Methylphenidate 4 (2)
2C-B 1 (<0.5)
Laughing gas (N20) 3 (1)
Dextromethorphan 1 (<0.5)
Ketamine 1 (<0.5)
Testosterone 1 (<0.5)
Intoxicative inhalant 1 (<0.5)
Antidepressants 1 (<0.5) 12 (6)
Neuroleptic agents 5 (2)
Unknown agent 16 (7)
Ethanol 103 (48) 75 (35)
2C-B = 2,5-dimethoxy-4-bromophenethylamine; GHB = γ-hydroxybutyrate; LSD = lysergic acid diethylamide; MDMA = 3,4-methylenedioxy-
methamphetamine
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the patients experienced were paranoia and persecutory de-
lusions of being followed, conspired against, harassed, and/
or spied on, in one case in combination with auditory hal-
lucinations (being followed by voices that were talking
Table 3: Clinical characteristics of acute recreational drug intoxications.
Number of cases N = 216 (%)
Cardiovascular
Chest pain 22 (10)
Palpitations 25 (12)
Dyspnoea 15 (7)
Hypertension (systolic blood pressure >180 mm Hg) 3 (1)
Tachycardia (>100 beats per minute) 68 (31)
Myocardial infarction 2 (1)
Elevated troponin (without infarction) 1 (<0.5)
Hyperthermia >39.0 °C 1 (<0.5)
Hypotension (systolic blood pressure <90 mm Hg) 4 (2)
Arrhythmias 2 (1)
QRS >120 msec 1 (<0.5)
QTc >450 msec 54 (25)
Psychiatric
Anxiety or nervousness 58 (27)
Psychosis 10 (5)
Hallucinations 8 (4)
Agitation or aggression 47 (22)
Panic attack 12 (6)
Insomnia 5 (2)
Suicidal ideation 6 (3)
Fear 2 (1)
Depersonalisation 1 (<0.5)
Neurological
Impaired consciousness, GCS <9 at presentation 17 (8)
Impaired consciousness, GCS 9-13 at presentation 19 (9)
Unconscious at presentation or pre-hospital 37 (17)
Impaired consciousness, GCS <15 (but >3), at presentation or pre-hospital 65 (30)
“Alert” at presentation 79 (37)
“Drowsy” at presentation 9 (4)
Vertigo 25 (12)
Headache 8 (4)
Paraesthesia 5 (2)
Alterations in perception 3 (1)
Seizure 10 (5)
Tremor 1 (<0.5)
Amnesia 12 (6)
Cerebellar features (e.g. ataxia) 5 (2)
Miosis 12 (6)
Mydriasis 15 (7)
Respiratory depression 18 (8)
Miscellanous
Hyperventilation 7 (3)
Nausea or vomiting 49 (23)
Diarrhoea 1 (<0.5)
Sweating 8 (4)
Haemoptysis 3 (1)
Abdominal pain 9 (4)
Dry mouth 2 (1)
Muscle cramps 4 (2)
Priapism 1 (<0.5)
Pneumothorax 1 (<0.5)
Sepsis 2 (1)
Injuries (fracture, wound etc) 9 (4)
Epistaxis 2 (1)
Elevated creatine kinase (>250 U/l) 58 (27)
Weakness, walking impairment 13 (6)
GCS = Glasgow coma scale
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about death and murder in Italian, although the patient
didn’t speak Italian), change of character, depersonalisa-
tion, and delusional parasitosis (two cases). Four of the pa-
tients (40%) were admitted to a psychiatric clinic and three
patients (30%) left the ED against medical advice.
Discussion
In this study we described acute medical problems due to
recreational drug use. The number of presentations due to
acute toxicity from recreational drugs was less than half
that due to acute alcohol intoxication during the same peri-
od. Most patients reported use of only one recreational
drug; however, more than one substance was analytically
detected in almost half of the cases (44%). Possible reasons
for this difference include the detection of substances in
blood that have been taken as co-medication and not for re-
creational purposes (e.g. benzodiazepines or opioids), sub-
stances that can be detected in blood after the acute intox-
ication (2–3 days in the case of THC) and are therefore not
directly related with the acute medical problem at presenta-
tion, and/or substances that have been given as a treatment
by the paramedics before presentation at the emergency de-
partment (e.g. benzodiazepines in the case of a seizure).
However, it can be assumed that in many cases the patients
did not report all the substances they had used. Ethanol co-
use was reported in almost half of the cases. Severe toxicity
was more frequent in combination with ethanol use, thus it
is possible that the impaired consciousness that contributed
to the characterisation of an intoxication as “severe” was in
many cases due to alcohol use and not directly related to
the recreational drugs. In accordance with the use in recre-
ational setting, most visits occurred during night time and/
or on weekends. In contrast to survey data showing that
amphetamines are more prevalent than other stimulants in
central Europe [1], amphetamines were not often reported
and/or analytically detected in our study. The substances
most commonly used were cocaine and cannabis, which is
more in line with data from south and west Europe [1].
The most commonly used prescription drugs (except
opioids) were benzodiazepines. Benzodiazepines were
taken in combination with other substances (12 of the 16
self-reported cases), most commonly with opioids (7 cases)
and/or cocaine (4 cases). There was one case of reported
antidepressant misuse. However, in most of the cases, anti-
depressants or neuroleptics were not reported to be misused
but analytically detected as part of the prescribed medica-
tion of the patients.
During the study period only two cases related to the use
of novel psychoactive substances were found, one case of
self-reported 2C-B use and one of analytically detected
pentylone.
In the case of pentylone, a 53-year-female patient was
admitted because of delusional parasitosis for the last 2
days and was later admitted to the psychiatric clinic. Be-
cause of chronic back pain the patient regularly used tra-
madol. Tramadol and pentylone were identified with LC-
MS. Pentylone is a β-keto-analogue of MDMA, similar to
methylone and butylone, and has recently been identified
as novel designer cathinone [9]. In-vitro studies show that
pentylone inhibits all of the monoamine transporters with
potency approximately equal to that of cocaine, but also
releases serotonin similarly to MDMA [10]. In our case
the delusional parasitosis was initially linked to tramadol
as part of a serotonin syndrome; however, the detection
of pentylone makes delusion and hallucinations caused by
pentylone a possible diagnosis [11, 12].
In the 2C-B case, a 30-year old-male reported having con-
sumed 2C-B 19 hours before presentation. The patient was
not able to sleep because of fear that he would forget to
breath. The somatic clinical examination and the routine
laboratory test were normal. 2C-B (or
2,5-dimethoxy-4-bromophenethylamine) is a synthetic
drug with hallucinogenic activity similar to LSD [13] and
has been reported to cause unpleasant hallucinations and
sympathomimetic stimulation [13, 14].
A fatal intoxication occurred in a 46-year-old patient
presenting with complaints of generalised pain, shivering,
drowsiness and dyspnoea after intravenous injection of
beer and cocaine. The medical history included intravenous
drug use for 20 years, a tetralogy of Fallot with three sur-
gical corrections, previous mitral valve endocarditis, hep-
atitis C, and an ischaemic stroke after injecting cocaine
into a central venous catheter. Transoesophageal echocardi-
ography showed severe mitral valve insufficiency with ve-
getations and four blood cultures were positive for Staphyl-
ococcus aureus, consistent with mitral valve endocarditis.
Because of the complexity of the case and lack of com-
pliance, a decision of conservative treatment was reached
including adequate antibiotic treatment. Within 3 weeks
the patient’s condition deteriorated and the patient died of
sepsis and heart failure.
Table 4: Severity of poisoning and outcome.
Number of cases N = 216 (%)
Severity of poisoning
Minor 81 (38)
Moderate 94 (44)
Severe 40 (19)
Fatal 1 (<0.5)
Outcome
Medically discharged home 146 (68)
Self-discharged 21 (10)
Admission to ward but not critical care unit 12 (6)
Admission to critical care unit 17 (8)
Admission to psychiatric clinic 20 (9)
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In two cases the patients suffered a myocardial infarction
(both without ST elevation). One of the two patients was a
43-year-old male who reported use of cocaine. Cardiovas-
cular problems including myocardial infarction are well-
known medical complications of cocaine [15, 16]. Cocaine
use has been observed in about 25% of 18–45-year-old pa-
tients with myocardial infarction [17]. Myocardial infarc-
tion may result from vasospasm [18] and excessive sym-
pathetic activation. However, most cardiac deaths occur in
patients with chronic cocaine use [19] and may involve
structural cardiovascular disease including myocardial hy-
pertrophy and microangiopathy [20, 21]. In line with these
findings, the patient in the present study was a chronic co-
caine user. The second patient with a myocardial infarc-
tion was a 31-year-male who reported use of amphetam-
ine and LSD. Except for tobacco smoking there was no
other known cardiovascular risk factor. Coronary angio-
graphy was normal. Acute myocardial infarction related
to amphetamine abuse is rare compared with cocaine. In
most of the cases the coronary arteriography is normal
[22]. A population-based epidemiological study of hospit-
alised young adults showed a modest, but significant, asso-
ciation between amphetamine abuse and acute myocardial
infarction [23]. Mechanisms may include coronary artery
vasospasm, catecholamine-induced platelet aggregation
and atherosclerotic plaque rupture, as well as excessive
catecholamine discharge resulting in ischaemic myocardial
necrosis and increased myocardial oxygen demand [22,
23]. Cases have been reported after inhalation, intravenous,
or oral administration [22].
In almost all of the cases with psychosis, use of psychoact-
ive substances known to induce transient paranoia or psy-
chosis [24] was self-reported or analytically detected.
In our study most of the patients who suffered a seizure had
used agents known to have a potential to induce seizures.
However, cannabis was self-reported in three cases (30%)
and was analytically detected in six cases (60%). Cannabis
is not associated with seizures and could actually have
a medical use for the treatment of epilepsy [25], as it is
thought to be protective for new-onset seizures [26]. On
the other hand, withdrawal (particularly from alcohol and/
or benzodiazepines) is associated with seizures [27]. In al-
cohol withdrawal seizures usually occur within 12 to 48
hours after the last drink, but may occur after only 2 hours
of abstinence [28]. This could have played a role in the four
cases with self-reported and/or analytically confirmed alco-
hol co-use in our study. Furthermore, in three cases the pa-
tients had a medical history of epilepsy. Another important
element that was not always known in our cases is the pres-
ence of triggers such as loud music, flashing lights, lack of
sleep, emotional stress (two of the patients were held by the
police at the moment of the seizure).
This study has limitations. There were missing data and the
initial patient histories and clinical data were not recorded
in a standardised manner. In addition, it is possible that pa-
tients who used synthetic cannabinoids went undetected,
because these cannot be detected with the LC-MS method
used in the present study. Similarly, co-use of GHB may
have gone undetected because of the small time period in
which it can be detected in blood or urine samples. On
the other hand, acute (co-) use of cannabis may have been
slightly overestimated because it can be detected up to 2
days after the acute intoxication in the serum assay used.
The data from only one large ED is not representative and
may reflect local drug using trends. Additionally, severe
toxicity may have been overrepresented because the ED
acts as referral centre for the Basel area, including parts of
France and Germany.
Our study has also several strengths. We had detailed pa-
tient and clinical data documentation, in contrast to studies
based on coded diagnoses or analyses of poison centre data.
Especially, the exposure was confirmed in blood for the
majority of the patients by use of immunoassays and LC-
MS, which, in combination with the self-reports, provides
a good picture of the actual recreational substances being
used.
In conclusion, most acute medical problems related to re-
creational drug toxicity were due to cocaine and cannabis
use, and mainly included sympathomimetic toxicity and/
or psychiatric disorders. Cases with acute toxicity linked
to novel psychoactive substances appear to be uncommon,
with only two novel substances (pentylone and 2C-B)
found. It could be that novel designer drugs are not fre-
quently used or infrequently lead to ED attendance.
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